{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:40:03Z","timestamp":1792014003526,"version":"4.4.0"},"reference-count":136,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/14737175.2023.2284305","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T10:07:09Z","timestamp":1700215629000},"page":"1113-1129","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Advances in amyloid-targeting monoclonal antibodies for Alzheimer\u2019s disease: clinical and public health issues"],"prefix":"10.1080","volume":"23","author":[{"given":"Simone","family":"Salemme","sequence":"first","affiliation":[{"name":"Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ancidoni","sequence":"additional","affiliation":[{"name":"National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"},{"name":"Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Locuratolo","sequence":"additional","affiliation":[{"name":"National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piscopo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lacorte","sequence":"additional","affiliation":[{"name":"National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Canevelli","sequence":"additional","affiliation":[{"name":"National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"},{"name":"Department of Human Neuroscience, \u201cSapienza\u201d University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[{"name":"National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_4_5_1","unstructured":"FDA Grants Accelerated Approval For Alzheimer\u2019s Drug. WA (DC): FDA\/News & Events\/FDA Newsroom\/Press Announcements 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug [last accessed 15 Jun 2023]"},{"key":"e_1_3_4_6_1","unstructured":"FDA grants accelerated approval for Alzheimer\u2019s disease treatment. WA (DC): FDA\/News & Events\/FDA Newsroom\/Press Announcements 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment [last accessed 15 Jun 2023]"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad159"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt237"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1531706"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0116-6"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148604.77591.67"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70140-0"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0108-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706441"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00614-5"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4857"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220046"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70015-7"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0424-5"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2909"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2018.02.002"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12109"},{"key":"e_1_3_4_27_1","unstructured":"Landmark Alzheimer\u2019s prevention trial unable to show significantly slower cognitive decline in inherited form of disease. Phoenix (AZ): Banner Health\/News and Media Resource Center 2023. Available from: https:\/\/www.bannerhealth.com\/newsroom\/press-releases\/alzheimers-trial-unable-to-show-significantly-slower-cognitive-decline-in-inherited-form-of-disease. [last accessed 15 Jun 2023]"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01369-8"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y"},{"key":"e_1_3_4_32_1","volume-title":"[Ad hoc announcement pursuant to art. 53 LR] roche provides update on phase III GRADUATE programme evaluating gantenerumab in early Alzheimer\u2019s disease","year":"2022","unstructured":"[Ad hoc announcement pursuant to art. 53 LR] roche provides update on phase III GRADUATE programme evaluating gantenerumab in early Alzheimer\u2019s disease. Basel: Roche\/Media\/Releases; 2022. last accessed 15 Jun 2023. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2022-11-14"},{"key":"e_1_3_4_33_1","unstructured":"Marketing authorization application for lecanemab as treatment for early Alzheimer\u2019s disease accepted by European Medicines Agency. Tokyo and Cambridge (Mass): Biogen\/News release 2023. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/marketing-authorization-application-lecanemab-treatment-early [last accessed 15 Jun 2023]"},{"key":"e_1_3_4_34_1","unstructured":"FDA Grants Accelerated Approval For Alzheimer\u2019s Drug. WA (DC): FDA\/News & Events\/FDA Newsroom\/Press Announcements 2023."},{"key":"e_1_3_4_35_1","unstructured":"Lecanemab receives priority review status in Japan. Tokyo and Cambridge Mass: EISAI\/News release\/2023 release 2023. Available from: https:\/\/www.eisai.com\/news\/2023\/news202312.html [last accessed 15 Jun 2023]"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.04.007"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215171"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2080-16.2016"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0420-17.2017"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn0901-887"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140741"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1134-4"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01409-2"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.10.029"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02418-3"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126355"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01308-6"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.09.068"},{"key":"e_1_3_4_52_1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-487_namenda.cfm"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.4610"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.4607"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.4604"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_4_58_1","unstructured":"Lin GA Whittington MD Synnott PG et al. Aducanumab for Alzheimer\u2019s disease: effectiveness and Value; final evidence report and meeting summary. Institute For Clinical And Economic Review 2021 Aug 5. https:\/\/icer.org\/assessment\/alzheimers-disease-2021\/."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00197-8"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3126"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7586"},{"key":"e_1_3_4_63_1","unstructured":"Center for drug evaluation and research. Application Number: 761178orig1s000. Clinical Review(s). WA (DC): FDA 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761178Orig1s000MedR_Redacted.pdf [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.34"},{"key":"e_1_3_4_65_1","unstructured":"CMS finalizes medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer\u2019s disease. CMS\/Newsroom\/policy medicare parts a & B 2022. Available from: https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_66_1","unstructured":"CMS announces plan to ensure availability of new Alzheimer\u2019s drugs. CMS\/Newsroom\/coverage prescription drugs 2023. Available from: https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-announces-plan-ensure-availability-new-alzheimers-drugs [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_67_1","unstructured":"FDA converts novel Alzheimer\u2019s disease treatment to traditional approval. Action follows confirmatory trial to verify clinical benefit. WA (DC): FDA\/News & Events\/FDA Newsroom\/Press Announcements 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_3_4_69_1","unstructured":"Peripheral and central nervous system (PCNS) drugs advisory committee meeting. FDA 2023. Available from: https:\/\/www.fda.gov\/media\/169264\/download [last accessed 15 Jun 2023]"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00768-w"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207156"},{"key":"e_1_3_4_73_1","unstructured":"Second Death Linked To Potential Antibody Treatment For Alzheimer\u2019s Disease. Science\/News\/Scienceinsider 2022. Available from: https:\/\/www.science.org\/content\/article\/second-death-linked-potential-antibody-treatment-alzheimer-s-disease [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_74_1","unstructured":"Scientists Tie Third Clinical Trial Death To Experimental Alzheimer\u2019s Drug. Science\/News\/Scienceinsider 2022. https:\/\/www.science.org\/content\/article\/scientists-tie-third-clinical-trial-death-experimental-alzheimer-s-drug [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215148"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12112"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.56"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2015.82"},{"key":"e_1_3_4_80_1","unstructured":"Donanemab Data Anchors Upbeat AAIC. Alzforum\/News 2023. Available from: https:\/\/www.alzforum.org\/news\/conference-coverage\/donanemab-data-anchors-upbeat-aaic [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3392"},{"key":"e_1_3_4_82_1","unstructured":"U.S. Food and drug administration issues complete response Letter for accelerated approval of donanemab. (IN)polis: Eli Lilly\/PRNewswire 2023. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/us-food-and-drug-administration-issues-complete-response-0 [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.102"},{"key":"e_1_3_4_85_1","unstructured":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. WA (DC): FDA\/Regulatory Information\/Search for FDA Guidance Documents 2023. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory [last accessed 7 Jul 2023]"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.104"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12388"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220303"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200817"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017201"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2607"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01228-7"},{"key":"e_1_3_4_93_1","unstructured":"Eisai Inc. A study to Confirm safety and efficacy of lecanemab in participants with early Alzheimer\u2019s disease (Clarity AD) In: ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2023 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03887455?intr=lecanemab&term=clarity&rank=1&tab=table. NLM Identifier: NCT033887455"},{"key":"e_1_3_4_94_1","unstructured":"Biogen. 221AD302 phase 3 study of aducanumab (BIIB037) in early Alzheimer\u2019s disease (EMERGE). In: ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2023 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02484547?intr=aducanumab&term=emerge&rank=1. NLM Identifier: NCT02484547"},{"key":"e_1_3_4_95_1","unstructured":"Biogen. 221AD301 phase 3 study of aducanumab (BIIB037) in early Alzheimer\u2019s disease (ENGAGE). In: ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2023 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02477800?intr=aducanumab&term=engage&rank=1. NLM Identifier: NCT02477800"},{"key":"e_1_3_4_96_1","unstructured":"Center for drug evaluation and research. Application number: 761178Orig1s000. Statistical Review(s). FDA 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761178Orig1s000StatR_Redacted.pdf [last accessed 25 Aug 2023]"},{"key":"e_1_3_4_97_1","unstructured":"Guidance for Industry. Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease. ISTCM 2013. Available from: https:\/\/isctm.org\/public_access\/FDAGuidance_AD_Developing_Drugs_Early_Stage_Treatment.pdf [last accessed 25 Aug 2023]"},{"key":"e_1_3_4_98_1","unstructured":"Early Alzheimer\u2019s disease: developing drugs for treatment. Guidance for Industry. FDA 2018. Available from: https:\/\/www.fda.gov\/media\/110903\/download [last accessed 25 Aug 2023]"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12280"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/gnz179"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-00984-y"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00659-6"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00445-0"},{"key":"e_1_3_4_104_1","unstructured":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical Product development and regulatory decision making. WA (DC): FDA\/Drugs\/Development & Approval Process | Drugs 2023. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical [last accessed 25 Aug 2023]"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201386"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00273-0"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00473-w"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2018.01.001"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.03.007"},{"key":"e_1_3_4_112_1","unstructured":"Surrogate Endpoint Resources for Drug and Biologic Development. WA (DC): FDA\/Drugs\/Development & Approval Process | Drugs\/Development Resources 2018. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development#:~:text=Usually%20clinical%20trials%20are%20needed FDA%20as%20evidence%20of%20benefit [last accessed 25 Aug 2023]"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780080407"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.0815"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1993.1112"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12366"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5205"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16298-1"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011542"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad175"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12433"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00628"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15286"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17390"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_3_4_128_1","unstructured":"Highlights of prescribing information. Aduhelm. FDA 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761178s005lbl.pdf [last accessed 25 Aug 2023]"},{"key":"e_1_3_4_129_1","unstructured":"Highlights of prescribing information. Leqembi. FDA 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269s001lbl.pdf [last accessed 25 Aug 2023]"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17r11772"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.07.024"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.118307"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.5.530"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207423"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-022-02118-8"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-021-00737-8"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2022.12.006"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-021-00533-w"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15007"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2023.2284305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T21:15:30Z","timestamp":1727212530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2023.2284305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":136,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/14737175.2023.2284305"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2023.2284305","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}